Document:

EX-10.14

 Exhibit 10.14 

Execution Version 
 First
Amendment to the 
 Amended and Restated Employment Agreement 

between Altimmune, Inc. and William J. Enright 

This First Amendment to the Amended and Restated Employment Agreement, effective as of January 18, 2017 (this
“Amendment”), is by and between Altimmune, Inc. (“Altimmune”) and William J. Enright (“Enright”). 

WHEREAS, Altimmune and Enright are parties to that certain Amended and Restated Employment Agreement, dated as of December 7, 2015 (the
“Existing Agreement”); 
 WHEREAS, Altimmune and Enright desire to amend the Existing Agreement as set forth in this
Amendment; and 
 WHEREAS, Section 15 of the Existing Agreement requires that any amendment to the Existing Agreement be in a written
agreement executed by Enright and the Chairman of the Company’s Board of Directors; 
 NOW, THEREFORE, in consideration of the mutual
promises and covenants contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

 

	 	1.	The first paragraph of the Existing Agreement is amended and restated in its entirety to read as follows: 

“This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of 7 December, 2015, by and
between William J. Enright (“Enright”) and Altimmune Inc. (f/k/a Vaxin, Inc.), a Delaware corporation (“Altimmune”). This Agreement will become effective upon the date (the “Effective Date”) that is the earlier to occur
of one of the following (each, an “IPO”): (x) the date of the underwriting agreement between Altimmune and the underwriter(s) managing the initial public offering of Altimmune’s common stock, pursuant to which such common stock is
priced for the initial public offering; and (y) the date of consummation of a transaction pursuant to which Altimmune becomes a wholly-owned subsidiary of a corporation (“Parent”) that has a class of securities registered under
Section 12 of the Securities Exchange Act of 1934; provided that if (i) Altimmune does not complete an IPO on or prior to June 30, 2017 or (b) Enright does not remain continuously employed by Altimmune from the date hereof
through the Effective Date, this Agreement shall be void ab initio (i.e., it shall never take effect) and the Prior Employment Agreement (as defined below) shall remain in full force and effect.” 

 

	 	2.	The fifth “WHEREAS” clause of the Existing Agreement is amended and restated in its entirety to read as follows: 

“WHEREAS, Altimmune and Enright both acknowledge that there is no assurance that Altimmune will complete an IPO on or prior to
June 30, 2017 or at all at any time and that if it does not, the Effective Date will not occur and this Agreement will not take effect; and”. 

	 	3.	Section 2 of the Existing Agreement is amended and restated in its entirety to read as follows: 

“Employment Term. Unless sooner terminated as provided elsewhere in this Agreement, Enright’s employment with
Altimmune under this Agreement shall begin on the Effective Date and end at 11:59 p.m. Eastern Time on December 31, 2018 (the “Initial Employment Period”). Commencing on January 1, 2019 and each January 1 thereafter
(the “Extension Date”), this Agreement shall automatically renew on the terms and conditions as then in effect for additional successive periods of one (1) year unless terminated by either party upon written notice to the other
party not less than ninety (90) days prior to the Extension Date. The Initial Employment Period and any extension or renewal thereof shall be referred to herein together as the “Employment Period.” Notwithstanding anything to
the contrary contained herein, the Employment Period is subject to termination pursuant to Section 6 hereof.” 
  

	 	4.	Section 3(c) of the Existing Agreement is amended and restated in its entirety to read as follows: 

“IPO Option Award. Subject to the approval of the Committee, on the Effective Date, Altimmune shall grant (or cause to be granted)
to Enright an option to purchase 133,395 shares of common stock (the “IPO Option”) under the Altimmune, Inc. 2016 Omnibus Incentive Plan, an equity incentive plan of Parent, or such other equity incentive plan in effect on the Effective
Date pursuant to which Enright is eligible to receive equity incentive awards (each, an “Equity Plan”). The exercise price of the IPO Option shall be equal to the initial public offering price per share of Altimmune’s common stock on
the Effective Date or if applicable, the closing price of Parent’s common stock on a national securities exchange on the Effective Date. One hundred percent (100%) of the IPO Option shall be unvested and unexercisable as of the Effective Date.
Commencing on the first anniversary of the Effective Date, twenty-five percent (25%) of the unvested portion of the IPO Option shall vest and become exercisable, and the aggregate remaining unvested portion of the IPO Option shall vest and become
exercisable in equal monthly installments over the thirty-six (36) month period following such anniversary date. Notwithstanding the foregoing, if the Committee, in its sole discretion, determines that
the IPO was successful, 50% of the unvested portion of the IPO Option shall immediately vest and become exercisable. For the avoidance of doubt, the Committee shall have the sole and absolute discretion to determine whether the IPO was successful
for purposes of the immediately preceding sentence. Other than as set forth in this Section 3(c), the IPO Option will be governed by the terms and conditions of the Equity Plan and the applicable stock option award agreement.” 

 

	 	5.	Section 3(d) of the Existing Agreement shall be amended by replacing the reference to “2016 Plan” with “Equity Plan”. 

 

	 	6.	Except as expressly amended herein, the terms and conditions of the Existing Agreement shall remain in full force and effect. 

[Signature page follows] 
  

  
 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written
above. 
  

							
	ALTIMMUNE, INC.	 		 	WILLIAM J. ENRIGHT
				
	By:	 	 /s/ David Drutz
	 		 	 /s/ William J. Enright

	Name:	 	David Drutz	 		 	
	Title:	 	Chairman of the Board	 		 	

  
 Signature Page to First
Amendment to the Employment Agreement - EnrightEX-10.15

 Exhibit 10.15 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of December 7, 2015 (the
“Effective Date”) by and between Elizabeth Czerepak (“Czerepak”) and Altimmune, Inc. (f/k/a Vaxin, Inc.), a Delaware corporation (“Altimmune”). 

WHEREAS, Czerepak currently serves as the Chief Financial Officer of Altimmune pursuant to that certain Offer Letter, by and between
Czerepak and Altimmune, dated as of March 26, 2015 (the “Offer Letter”); 
 WHEREAS, the Offer Letter expressly
contemplates that Altimmune and Czerepak will enter into this Agreement to govern the terms and conditions of Czerepak’s employment relationship with Altimmune; 

WHEREAS, in connection with the execution of this Agreement, the Board of Directors of Altimmune (the “Board”) or an
authorized committee thereof and Czerepak desire to terminate and supersede in its entirety, subject to Section 9 of this Agreement, the Offer Letter as of the Effective Date pursuant to the terms hereof to assure Altimmune of Czerepak’s
continued employment in an executive capacity and to compensate her therefor; and 
 WHEREAS, Czerepak acknowledges that, in
executing this Agreement, she has had a reasonable opportunity to seek the advice of independent legal and tax counsel, and has read and understood all of the terms and provisions of this Agreement. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Titles, Duties and
Responsibilities. 
 (a) Title and Duties. During the Employment Period (as defined in Section 2 below), Czerepak shall
serve as Chief Financial Officer of Altimmune and shall have such duties, responsibilities and authority commensurate with such position, and such additional duties and responsibilities commensurate with such position as shall be determined from
time to time by the Chief Executive Officer of Altimmune (the “CEO”). 
 (b) Reporting Responsibilities. Czerepak
shall report directly to the CEO. 
 (c) Conflicts of Interest and Compliance with Laws. Except as specifically set forth in this
Section 1(c), during the Employment Period, Czerepak shall devote her entire time, attention, energies and business efforts to the affairs of Altimmune. Except as set forth below, during the Employment Period, Czerepak shall not, without the
prior written consent of the Board (x) engage, directly or indirectly, in any other business activity that materially interferes with her duties as set forth in this Agreement and/or that creates a conflict of interest, (y) act as a
proprietor, partner, director, officer, executive, consultant, advisor, agent, representative or any other capacity of any entity other than Altimmune and its divisions, subsidiaries and other affiliated entities, regardless of whether such activity
is for gain, profit or other pecuniary advantage, or (z) allow or cause Altimmune to participate in any transaction 

 
with Czerepak, any of her relatives (other than as employees of Altimmune), or any entity in which Czerepak or any of her relatives has an interest. Czerepak further agrees that she shall not
knowingly take any action, or authorize the taking of any action, that contravenes any applicable federal, state, municipal or other political subdivision ordinance, statute or rule, regulation or order of any jurisdiction. Czerepak agrees to
immediately disclose to the Board any relationship, action or activity that may potentially be subject to the provisions of this Section 1(c). 

2. Employment Term. Unless sooner terminated as provided elsewhere in this Agreement, Czerepak’s employment with Altimmune
under this Agreement shall begin on the Effective Date and end at 11:59 p.m. Eastern Time on December 31, 2017 (the “Initial Employment Period”). Commencing on January 1, 2018 and each January 1 thereafter (the
“Extension Date”), this Agreement shall automatically renew on the terms and conditions as then in effect for additional successive periods of one (1) year unless terminated by either party upon written notice to the other
party not less than ninety (90) days prior to the Extension Date. The Initial Employment Period and any extension or renewal thereof shall be referred to herein together as the “Employment Period.” Notwithstanding anything to
the contrary contained herein, the Employment Period is subject to termination pursuant to Section 6 hereof. 
 3. Salary, Bonus
and Other Compensation. During Czerepak’s employment, Altimmune shall provide the following salary, bonus and other compensation to Czerepak: 

(a) Base Compensation. Altimmune shall pay Czerepak an initial annual base salary of Two Hundred Ninety Thousand Dollars ($290,000) per
annum (or, upon the consummation of a Qualified IPO (as defined in Exhibit A hereto), the base salary shall be Three Hundred Twenty-Five Thousand Dollars ($325,000) per annum) (such salary, as applicable, “Base Salary”), payable in
substantially equal installments in accordance with Altimmune’s normal payroll practices. Czerepak’s compensation shall be evaluated and adjusted by the Compensation Committee of the Board (the “Committee”) on at least an
annual basis, provided that in no event shall Czerepak’s Base Salary be reduced while this Agreement is in effect. 
 (b) Annual
Bonus. In addition to the Base Salary, during each year of the Employment Period, Czerepak will be eligible for an annual cash bonus (“Annual Bonus”) with a target award equal to thirty percent (30%) of the Base
Salary, prorated for any partial periods. The Annual Bonus will be subject to all of the terms and conditions of the applicable bonus plan. The actual Annual Bonus payouts will be based on achievement of the individual and/or company performance
criteria established for the applicable fiscal year by the Committee in its sole and absolute discretion. Czerepak must be actively employed on December 31st of the applicable fiscal year to
be eligible for an Annual Bonus payment. The Annual Bonus shall be paid no later than the March 15th of the fiscal year immediately following the fiscal year in which such Annual Bonus was
earned. 
 (c) Equity Awards. Czerepak will be entitled to participate in the Altimmune 2016 Omnibus Incentive Plan or such other
equity based long-term incentive compensation plan, program or arrangement generally made available to senior executive officers of Altimmune from time to time, as determined by the Committee in its sole and absolute discretion. 

  
 2 

 4. Benefits. During the Employment Period, Czerepak shall be eligible for
participation in and shall receive all benefits under welfare benefit, savings and retirement plans provided by Altimmune (including, but not limited to, life insurance, disability insurance, medical insurance, dental insurance) to the extent
applicable generally to senior executives of Altimmune, and consistent with the following specific agreements: 
 (a) Vacation.
Czerepak will be entitled to twenty (20) days of paid vacation and six (6) days of personal and sick leave each year during the Employment Period. Czerepak is permitted to carry over a maximum of twelve (12) days of personal and sick
leave per year, subject to applicable law. 
 (b) Health, Life, Vision and Disability Insurance. Czerepak will be entitled to
participate in all health, vision and dental insurance programs provided by Altimmune to the extent applicable generally to senior executives of Altimmune. 

5. Reimbursement of Business Expenses. Altimmune shall reimburse Czerepak for all reasonable and customary out-of-pocket business
expenses incurred by Czerepak in the course of her duties (to include monthly expenses to maintain cellular telephone service), in accordance with Altimmune’s policies as in effect from time to time. Czerepak shall be required to submit to
Altimmune appropriate documentation supporting such out-of-pocket business expenses as a prerequisite to reimbursement in accordance with such policies. Notwithstanding anything herein to the contrary or otherwise, except to the extent any expense
or reimbursement described in this Agreement does not constitute a “deferral of compensation” within the meaning of Section 409A of the Code and the Treasury regulations and other guidance issued thereunder, any expense or
reimbursement described in this Agreement shall meet the following requirements: (i) the amount of expenses eligible for reimbursement provided to Czerepak during any calendar year will not affect the amount of expenses eligible for
reimbursement to Czerepak in any other calendar year; (ii) the reimbursements for expenses for which Czerepak is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the
applicable expense is incurred; (iii) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit; and (iv) the reimbursements shall be made pursuant to objectively
determinable and nondiscretionary company policies and procedures regarding such reimbursement of expenses. 
 6. Termination
Provisions. 
 (a) Termination by Altimmune for Cause or Termination by Czerepak without Good Reason. Altimmune may terminate
Czerepak’s employment immediately for Cause (as defined below) and Czerepak may terminate her employment at any time without Good Reason upon providing Altimmune at least thirty (30) days advance written notice. Upon such termination,
Altimmune shall provide Czerepak with the following: (i) payment of any accrued Base Salary through and including the date of Czerepak’s termination to the extent not theretofore paid; (ii) any accrued and unused vacation pay through
and including the date of Czerepak’s termination; (iii) any unreimbursed business expenses in accordance with Section 5 hereof, and (iv) such accrued and vested rights or benefits as may be due to Czerepak under any Altimmune
sponsored employee benefits plans payable in accordance with the terms and conditions of such plans (the payments and benefits referred to in subclauses (i) through 

  
 3 

 
(iv) above shall be collectively referred to as the “Accrued Obligations”). Except as provided in this Section 6(a), termination pursuant to this Section 6(a) shall
terminate any other rights Czerepak may have under this Agreement and shall relieve Altimmune of any other obligations it may have under this Agreement. 

For purposes of this Agreement, termination for Cause shall mean the termination of Czerepak’s employment by Altimmune due to: (i) a
material breach by Czerepak of her fiduciary duties to Altimmune; (ii) a material breach by Czerepak of this Agreement after being given written notice of such breach and a failure to cure within thirty (30) days of such notice;
(iii) Czerepak’s willful failure or refusal to follow Altimmune’s written policies after being given written notice of said failure or refusal and a failure to cure within thirty (30) days of such notice;
(iv) Czerepak’s conviction of, or plea of guilty or nolo contendere, to a felony; and/or (v) Czerepak’s continuing and willful refusal to act as directed by the Board or CEO (other than refusal resulting from incapacity
due to physical or mental illness), after written notice is delivered to Czerepak within sixty (60) days of such refusal which identifies said refusal and sets forth a plan of corrective action and a failure to cure within thirty (30) days
of such notice. 
 (b) Termination by Altimmune without Cause or Resignation by Czerepak for Good Reason. Altimmune may terminate
Czerepak’s employment without Cause at any time upon prior written notice to Czerepak and Czerepak may terminate her employment for Good Reason (as defined below). Upon such termination, subject to Czerepak’s continued compliance with the
restrictive covenants set forth in Section 7, Altimmune shall provide Czerepak with the following: 
 (i) continued payment of the Cash
Severance Amount (as defined below) in equal monthly installments during the applicable severance period (as determined below) following the effective date of such termination and otherwise payable in accordance with Altimmune’s normal payroll
practices. As used herein, the “Cash Severance Amount” shall be equal to six (6) months of Czerepak’s Base Salary existing at the time of such termination payable over the six (6) month period following such
termination, except that if such termination occurs within the one (1) year period commencing on the occurrence of a Change in Control (as defined below), the Cash Severance Amount shall instead be equal to the sum of twelve (12) months of
Czerepak’s Base Salary (existing at the time of such termination) plus Czerepak’s target Annual Bonus for the year of termination, payable over the twelve (12) month period following such termination; 

(ii) subject to Czerepak’s timely election, and the availability, of continuation coverage under Part 6 of Title I of the Employment
Retirement Income Security Act of 1974 (as amended) and Section 4980B of the Code (“COBRA”), Altimmune will pay monthly, on Czerepak’s behalf, a portion of the cost of such coverage for the six (6) months after the
date of such termination, which payments will be equal to the amount of the monthly premium for such coverage, less the amount that Czerepak would have been required to pay if Czerepak had remained an active employee of Altimmune (the “COBRA
Assistance”); provided, however, if at any time Altimmune determines that the COBRA Assistance would result in a violation of the non-discrimination rules under Section 105(h)(2) of the Internal Revenue Code of 1986, as
amended (the “Code”) or any other applicable laws, statute or regulation of similar effect (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education
Reconciliation Act), then in lieu of providing the COBRA Assistance, Altimmune will instead pay Czerepak fully taxable cash payments equal to, and paid at the same time as, the COBRA Assistance would have otherwise been paid, subject to applicable
tax withholdings; 

  
 4 

 (iii) any unpaid prior year’s Annual Bonus, payable by Altimmune to Czerepak at the same
time annual bonuses in respect of the prior year are generally paid to senior executives of Altimmune; 
 (iv) the Accrued Obligations; and

 (v) if such termination occurs within the one (1) year period commencing on the occurrence of a Change in Control, accelerated
vesting of all unvested equity awards then outstanding and held by Czerepak (for the avoidance of doubt, if such termination does not occur during such one (1) year period, then any accelerated vesting of unvested equity awards shall be at the
discretion of the Committee). 
 For purposes of this Agreement, resignation for Good Reason shall mean the resignation by Czerepak of her
employment due to: (a) a reduction in Czerepak’s Base Salary or target Annual Bonus opportunity; (b) a material diminution in Czerepak’s authority, duties or responsibilities; or (c) a relocation by Altimmune of
Czerepak’s principal place of business for the performance of her duties under this Agreement to a location that is anywhere outside of a 50-mile radius of Gaithersburg, Maryland; provided, however, that Czerepak must notify
Altimmune within ninety (90) days of the occurrence of any of the foregoing conditions that she considers to be a “Good Reason” condition and provide Altimmune with thirty (30) days in which to cure the condition. If Czerepak
fails to provide this notice and cure period prior to her resignation, or resigns more than six (6) months after the initial existence of the condition, her resignation will not be deemed to be for “Good Reason.” 

For purposes of this Agreement, “Change in Control” means the occurrence of either (i) an acquisition from stockholders
of Altimmune (including through purchase, reorganization, merger, consolidation or similar transaction), directly or indirectly, in one or more transactions by a Person (other than any Person or group of Persons consisting solely of shareholders of
Altimmune as of the date immediately prior to the consummation of the transaction) of beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities representing 50% or more of the combined voting power of the
securities of Altimmune entitled to vote generally in the election of directors of the Board, calculated on a fully diluted basis after giving effect to such acquisition, or (ii) the sale or other disposition, directly or indirectly, of all or
substantially all of the assets of Altimmune and its subsidiaries, taken as a whole, to any Person (other than any Person or group of Persons consisting solely of shareholders of Altimmune as of the date immediately prior to the consummation of the
transaction). For the avoidance of doubt, a transaction effected primarily for the purpose of (x) an equity financing of Altimmune, (y) the reincorporation of Altimmune in a different state, or (z) the formation of a holding company
that will be owned exclusively by Altimmune’s stockholders, shall not be a Change in Control for purposes of this Agreement. A “Person” means any individual, entity or group within the meaning of Section 13(d)(3) or 14(d)(2) of
the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, other than employee benefit plans sponsored or maintained by Altimmune and by entities controlled by Altimmune or an underwriter of the capital stock of
Altimmune in a registered public offering. 

  
 5 

 (c) Death or Disability. Czerepak’s employment shall terminate automatically upon
Czerepak’s death. Subject to applicable law, Altimmune may terminate Czerepak’s employment due to Czerepak’s Disability (as defined below). Upon any such termination, Altimmune shall provide Czerepak (or her estate as the case may be)
with the Accrued Obligations through the date of termination. The term “Disability” shall mean Czerepak becoming physically or mentally disabled such that she is unable to perform her duties to Altimmune for a period of 90
consecutive days. 
 (d) Expiration of Employment Term. In the event notice of termination is provided by Czerepak in accordance with
Section 2, Czerepak’s employment shall terminate upon the expiration of the Employment Period. Upon such termination, Altimmune shall provide Czerepak with the Accrued Obligations through the date of termination and her Annual Bonus. 

(e) Limits. Notwithstanding anything herein to the contrary, Altimmune’s obligation to make any payments or benefits to Czerepak
upon termination of her employment under the circumstances described in Section 6(b) (other than the Accrued Obligations) and 6(d) (other than the Accrued Obligations) is conditioned upon Czerepak’s execution, delivery and
non-revocation of a valid and enforceable release of claims arising in connection with Czerepak’s employment and termination or resignation of employment with Altimmune and its affiliates (the “Release”) that becomes effective
not later than sixty (60) days after the date of such termination or resignation of employment. Altimmune shall provide the form of the Release to Czerepak within seven (7) days following the date of Czerepak’s termination or
resignation of employment. Subject to the foregoing and Section 21 hereof, the Cash Severance Amount will commence to be paid to Czerepak on the sixtieth (60th) day following Czerepak’s termination or resignation of employment, and
such first payment shall include payment of any amounts that would otherwise be due prior thereto. On any termination entitling Czerepak to the payments and benefits under Section 6(b) or 6(d), Altimmune and its affiliates shall have no further
obligation to make payments under this Agreement other than as specifically provided for in such section. 
 (f) Resignation from All
Positions. Unless the parties otherwise agree in writing, upon the termination or resignation of Czerepak’s employment with Altimmune for any reason, Czerepak shall be deemed to have resigned, as of the date of such termination or
resignation, from and with respect to all positions Czerepak then holds as an officer, director or employee with Altimmune and any of its affiliates. 

7. Secrecy, Non-Solicitation and Non-Competition. 

(a) Secrecy. During the Employment Period and thereafter, Czerepak covenants and agrees that she will not, except in performance of
Czerepak’s obligations to Altimmune, or with the prior written consent of Altimmune pursuant to the authority granted by a resolution of the Board, directly or indirectly, disclose any secret or confidential information that she may learn or
has learned by reason of her association with Altimmune or use any such information. The term “secret or confidential information” includes, without limitation, information not previously disclosed to the public or to the trade by
Altimmune’s management with respect to Altimmune’s products, facilities and methods, trade secrets and other intellectual property, systems, procedures, manuals, confidential reports, product price

  
 6 

 
lists, customer lists, member lists, financial information (including the revenues, costs or profits associated with any Altimmune’s products), business plans, prospects, employee or
employees, compensation, or opportunities but shall exclude any information already in the public domain which has been disclosed to the public during the normal course of Altimmune’s business. Notwithstanding anything herein to the contrary,
nothing in this Agreement shall be construed to prohibit Czerepak from reporting possible violations of federal or state law or regulations to any governmental agency or entity, including but not limited to the Department of Justice, the Securities
and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal or state law or regulation. Czerepak does not need the prior authorization of
Altimmune to make any such reports or disclosures and Czerepak is not required to notify Altimmune that she made such reports or disclosures. 

(b) Non-solicitation of Clients and Customers. Czerepak covenants and agrees that during the Employment Period and for a period of six
(6) months thereafter, she will not solicit, either directly or indirectly, any customer or client of Altimmune on behalf of any direct competitor of Altimmune for the purpose of diverting business from Altimmune. This Agreement extends to
prevent Czerepak from soliciting on behalf of Czerepak or any other individual or entity that seeks to compete with Altimmune. 
 (c)
Non-solicitation of Employees. Czerepak covenants and agrees that during the Employment Period and for a period of six (6) months thereafter, she shall not directly or indirectly, on her behalf or on behalf of any person or other entity,
solicit or induce, or attempt to solicit or induce, any person who is an employee of Altimmune, to terminate his or her employment with Altimmune. 

(d) Noncompetition. Czerepak covenants and agrees that during the Employment Period and for a period of six (6) months thereafter,
she will not directly or indirectly work for or engage in sales, marketing or related activities on behalf of herself or any other person or entity that is a direct competitor of Altimmune. 

(e) Equitable Relief. Czerepak acknowledges and agrees that the services performed by her are special, unique and extraordinary in that,
by reason of Czerepak’s employment, Czerepak may acquire confidential information and trade secrets concerning the operation of Altimmune, or that Czerepak may have contact with or obtain knowledge of Altimmune’s members or prospects, the
use or disclosure of which could cause Altimmune substantial loss and damages, which could not be readily calculated and for which no remedy at law would be adequate. Accordingly, Czerepak acknowledges and agrees that Altimmune shall be entitled to
obtain a temporary restraining order and/or a preliminary or permanent injunction restraining Czerepak from engaging in activities prohibited by this Section 7 or such other relief as may be required to specifically enforce any of the covenants
in this Section 7. Czerepak acknowledges and agrees that Altimmune shall be entitled to its attorneys’ fees and court costs should Altimmune successfully pursue legal action to enforce its rights under this Section 7. 

  
 7 

 (f) Return of Property. Upon termination or resignation of Czerepak’s employment with
Altimmune, Czerepak shall promptly supply to Altimmune all property, keys, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data and any other tangible
product or document which has been produced by, received by or otherwise submitted to Czerepak during or prior to her employment with Altimmune, and any copies thereof in Czerepak’s (or capable of being reduced to Czerepak’s) possession.

 (g) Survival. Any termination of Czerepak’s employment, of the Employment Period or of this Agreement (or breach of this
Agreement by Altimmune or Czerepak) shall have no effect on the continuing operation of this Section 7. 
 8. Governing
Law. This Agreement is made and entered into in the State of Maryland, without regard to conflict of laws rules, and the laws of the State of Maryland shall govern its validity and interpretation in the performance by the parties of their
respective duties and obligations. 
 9. Entire Agreement. This Agreement constitutes the entire agreement between the
parties with respect to the matters described herein and supersedes all prior agreements and understandings both written and oral, among the parties with respect to the subject matter hereof (including, without limitation, the Offer Letter), and
there are no representation, warranties or commitments, other than those in writing executed by the parties hereto; provided, however, that Czerepak’s reimbursement obligations to Altimmune for the sign-on bonus and the relocation
allowance under the Offer Letter shall survive until the first anniversary of Czerepak’s employment commencement date with Altimmune. 

10. Consent to Venue. Any dispute, controversy, or claim arising out of or relating to this Agreement or the breach thereof,
arising out of or relating in any way to the employment of Czerepak or termination thereof, shall be brought in the Federal courts located in the State of Maryland; provided, however, that if any of the aforementioned courts is found to lack subject
matter jurisdiction, then to the exclusive jurisdiction of the state courts in the State of Maryland. By executing and delivering this Agreement, each party, for itself or herself and in connection with its or her properties, irrevocably
(a) accepts generally and unconditionally the exclusive jurisdiction and venue of such courts; (b) waives any defense of forum non conveniens; (c) agrees that service of all process in any such proceeding in any such court may be made
by registered or certified mail, return receipt requested, to the applicable party at its address provided herein; and (d) agrees that service as provided in clause (c) above is sufficient to confer personal jurisdiction over the
applicable party in any such proceeding in any such court, and otherwise constitutes effective and binding service in every respect. 

11. WAIVER OF JURY TRIAL. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY DISPUTE,
CONTROVERSY OR CLAIM, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE, AMONG THE PARTIES HERETO ARISING OUT OF OR RELATING IN ANY WAY TO THE EMPLOYMENT OF CZEREPAK OR TERMINATION THEREOF OR FOR ANY COUNTERCLAIM THEREIN. THE PARTIES HERETO MAY FILE
AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT OF COMPETENT JURISDICTION AS PROVIDED HEREIN AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. 

  
 8 

 12. Assistance in Litigation. Czerepak shall make herself available, upon the
request of Altimmune, to testify or otherwise assist in litigation, arbitration, or other disputes involving Altimmune, or any of the directors, officers, executives, subsidiaries, or parent corporations of Altimmune, at no additional cost during
the Employment Period and at any time following the termination of Czerepak’s employment for any reason; provided, however, in the event such request is made by Altimmune after the Employment Period, Czerepak shall be reimbursed for any
reasonable out-of-pocket expenses incurred with respect thereto and shall also be paid a reasonable daily stipend based on her Base Salary at the time of termination. 

13. Notices. Any notice or communication required or permitted to be given to the parties shall be delivered personally or sent
by registered or certified mail, postage prepaid and return receipt requested, and addressed or delivered as follows, or to such other address as the party addressed may have substituted by notice pursuant to this Section. 

 

	 	(a)	If to Altimmune, to: 

 Altimmune, Inc. 

19 Firstfield Road, Suite 200 

Gaithersburg, Maryland 20878 

ATTN: Chief Executive Officer 
  

	 	(b)	If to Czerepak, to: 

 The last address on file with Altimmune at the time of Notice. 

14. Binding Agreement. This Agreement shall inure to the benefit of and be enforceable by Czerepak and her personal or legal
representatives, executors, administrators, successors, heirs, distributees, devises and legatees. This Agreement shall inure to the benefit of and be enforceable by Altimmune and any of its successors and assigns. Altimmune will require any
successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of Altimmune to assume expressly and agree to satisfy all of the obligations under this Agreement
in the same manner and to the same extent that Altimmune would be required to satisfy such obligations if no such succession had taken place. As used in this Agreement, “Altimmune” shall mean “Altimmune” as hereinbefore defined
and any successor to its respective businesses and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise. 

15. Amendment. This Agreement may not be amended or modified otherwise than by a written agreement executed by Czerepak and the
Chairman of the Board or their respective successors and legal representatives. 
 16. Construction. This Agreement shall not
be construed against any party by reason of the drafting or preparation hereof. 
 17. Captions. The captions of this
Agreement are inserted for convenience and are not part of the Agreement. 

  
 9 

 18. Severability. In case any one or more of the provisions contained in this
Agreement shall for any reason be held to be invalid, illegal, or unenforceable in any other respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement. This Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been part of the Agreement and there shall be deemed substituted therefore such other provision as will most nearly accomplish the intent of the parties to the extent permitted by the
applicable law. 
 19. Survivorship. Upon the expiration or other termination of this Agreement or termination of
Czerepak’s employment for any reason, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement.

 20. Withholding. Altimmune may withhold from any amounts payable under this Agreement such Federal, state, local or
foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation. 
 21.
Section 409A.  
 (a) Although Altimmune does not guarantee the tax treatment of any payments or benefits provided
under this Agreement, it is intended that this Agreement will comply with, or be exempt from, Code Section 409A to the extent this Agreement (or any benefit or payment provided hereunder) is subject thereto, and this Agreement shall be
interpreted on a basis consistent with such intent. 
 (b) Notwithstanding any provision to the contrary in this Agreement, if Czerepak is
deemed on the date of her “separation from service” (within the meaning of Treas. Reg. Section 1.409A-1(h)) with Altimmune to be a “specified employee” (within the meaning of Treas. Reg. Section 1.409A-1(i)), then with
regard to any payment or benefit that is considered non-qualified deferred compensation under Code Section 409A payable on account of a “separation from service” that is required to be delayed pursuant to Code
Section 409A(a)(2)(B) of the Code (after taking into account any applicable exceptions to such requirement), such payment or benefit shall be made or provided on the date that is the earlier of (i) the date immediately following the
expiration of the six-month period measured from the date of Czerepak’s “separation from service,” and (ii) the date of Czerepak’s death (the “Delay Period”). Upon the expiration of the Delay Period, all
payments and benefits delayed pursuant to this Section 21(b) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Czerepak in a lump sum and any
remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. 

(c) Notwithstanding any provision of this Agreement to the contrary, for purposes of any provision of this Agreement providing for the payment
of any amounts or benefits upon or following a termination of employment that are considered deferred compensation under Code Section 409A, references to Czerepak’s “termination of employment” (and corollary terms) with Altimmune
shall be construed to refer to Czerepak’s “separation from service” (within the meaning of Treas. Reg. Section 1.409A-1(h)) with Altimmune. 

  
 10 

 (d) Whenever payments under this Agreement are to be made in installments, each such installment
shall be deemed to be a separate payment for purposes of Code Section 409A. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., “payment shall be made within thirty (30) days
following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of Altimmune. Notwithstanding anything herein, Czerepak shall be responsible for payment of any applicable personal
tax liabilities associated with the receipt of income or benefits pursuant to this Agreement. 
 22. Section 280G. 

 (a) Notwithstanding anything contained in this Agreement to the contrary, (i) to the extent that any payment or distribution of
any type to or for the benefit of Czerepak by Altimmune, any affiliate thereof, any person or entity who acquires ownership or effective control of Altimmune or ownership of a substantial portion of Altimmune’s assets (within the meaning of
Section 280G of the Code and the regulations thereunder), or any affiliate of such person or entity, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (the “Payments”)
constitutes “parachute payments” (within the meaning of Section 280G of the Code), and if (ii) such aggregate Payments would, if reduced by all federal, state and local taxes applicable thereto, including the excise tax imposed
under Section 4999 of the Code (the “Excise Tax”), be less than the amount Czerepak would receive, after all taxes, if Czerepak received aggregate Payments equal (as valued under Section 280G of the Code) to only three
times Czerepak’s “base amount” (within the meaning of Section 280G of the Code), less $1.00, then (iii) such Payments shall be reduced (but not below zero) if and to the extent necessary so that no Payments to be made or
benefit to be provided to Czerepak shall be subject to the Excise Tax; provided, however, that, solely to the extent applicable, Altimmune shall use its reasonable best efforts to obtain shareholder approval of the Payments provided
for in this Agreement in a manner intended to satisfy requirements of the “shareholder approval” exception to Section 280G of the Code and the regulations promulgated thereunder, such that payment may be made to Czerepak of such
Payments without the application of an Excise Tax. If the Payments are so reduced, Altimmune shall reduce or eliminate the Payments (x) by first reducing or eliminating the portion of the Payments which are not payable in cash (other than that
portion of the Payments subject to clause (z) hereof), (y) then by reducing or eliminating cash payments (other than that portion of the Payments subject to clause (z) hereof) and (z) then by reducing or eliminating the portion
of the Payments (whether payable in cash or not payable in cash) to which Treasury Regulation § 1.280G-1 Q/A 24(c) (or successor thereto) applies, in each case in reverse order beginning with payments or benefits which are to be paid the
farthest in time. 
 (b) The determination of whether the Payments shall be reduced as provided in Section 22(a) hereof and the amount
of such reduction shall be made at Altimmune’s expense by an independent public accounting firm of national reputation selected by Altimmune (the “Accounting Firm”). The Accounting Firm shall provide its determination (the
“Determination”), together with detailed supporting calculations and documentation, to Altimmune and Czerepak within ten (10) days after Czerepak’s final day of employment. If the Accounting Firm determines that no Excise
Tax is payable by Czerepak with respect to the Payments, it shall furnish Czerepak with an opinion reasonably acceptable to her that no Excise Tax will be imposed with respect to any such payments and, absent manifest error, such Determination shall
be binding, final and conclusive upon Altimmune and Czerepak. 

  
 11 

 23. Counterparts. This Agreement may be executed simultaneously in two or more
counterparts, each of which shall be deemed an original, but all of which shall together constitute one in the same Agreement. 

  
 12 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written
above. 
  

									
	ALTIMMUNE, INC.:	 		 	ELIZABETH CZEREPAK:
				
	By:	 	 /s/ William J. Enright
	 		 	 /s/ Elizabeth Czerepak

		 	Chief Executive Officer	 		 	
			
	Date: December 7, 2015	 		 	Date: December 7, 2015

  
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]